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ungi, including both yeasts and many moulds (Zygomycetes
eing a major exception). Detection of 1,3-beta, D-glucan
s approved for clinical use though cost and technical issues
ave limited its clinical acceptance for routine use. These
ethods are aimed at providing non-invasive and rapid
ethods for establishing a diagnosis of these often lethal
nfections.
oi:10.1016/j.ijid.2010.02.2194
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pidemiology of P. vivax Malaria in the World and Latin
merica
.J. Rodriguez-Morales
Universidad Central de Venezuela, Caracas, DC, Venezuela
Morbidity and mortality burden of malaria, particu-
arly in children, represents a public health threat also in
hose countries from regions such as South East Asia and
atin America with moderate to low levels of transmis-
ion. Between them epidemiological patterns are similar,
ower malaria inoculation rates sustained with a predom-
nant prevalence of Plasmodium vivax infection. Malaria
ortality in these areas has been mainly attributed to P.
alciparum, but its direct and indirect burden has not well
eﬁned. These patterns are increasingly causing concern
n some countries. Globally, ∼250 million clinical episodes
ccur annually (2.7 in Latin America); most of these are
aused by infection with P. falciparum and P. vivax. Although
. falciparum is justiﬁably regarded as the greater menace
ecause of its high mortality, widespread antimalarial drugs
esistance and its dominance on Africa, malaria due to P.
ivax has also placed signiﬁcant burdens on health, longevity
nd general prosperity of large sections of the human pop-
lation. The debilitating impact of P. vivax malaria remains
igh, unacceptable and preventable for well over one billion
nhabitants of the planet. Complicated and even fatal cases
f malaria due to P. vivax have been increasingly reported
n the medical literature. Plasmodium vivax can cause both
equestration-related and non-sequestration-related com-
lications of severe malaria, including cerebral malaria,
enal failure, circulatory collapse, severe anemia, abnormal
leeding, ARDS and jaundice. In Latin America the burden of
ortality due to malaria, although decreasing, is still signiﬁ-
ant. Powerful antimalarial campaigns in the region directed
ainly to P. falciparum achieved a signiﬁcant reduction of
ortality in the last century. Evidence suggests that P. vivax
an imposes a signiﬁcant burden of mortality that may have
esulted from its interaction with other diseases and con-
itions. These and other epidemiological issues are herein
iscussed at a global level and focused in Latin America.
oi:10.1016/j.ijid.2010.02.2195
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olecular Epidemiology of P. vivax: tools for Malaria Con-
rol
. Escalante
Arizona State University, Tempe, AZ, USA
Plasmodium vivax is the most prevalent human malarial
arasite in several areas of Asia and South-Central America.
lthough Plasmodium genomics is improving our knowledge
f the organism’s complex biology, population-based inves-
igations are needed to explore the extent of the parasites’
enetic variation, how the observed variation is geograph-
cally distributed, and how such diversity affects or can
e used to assess the success of control measures. Unfor-
unately, the lack of suitable in vitro culturing methods
or P. vivax imposes the use of ﬁeld specimens for popu-
ation studies. Such circumstances have limited molecular
pidemiologic and genetic diversity studies to a handful of
ntigens and few genetic markers that could be considered
eutral, that is, that are not expected to be under natu-
al selection by the immune response or antimalarial drugs.
irst, I will discuss the emerging patterns on the genetic
iversity of P. vivax using neutral markers and explore
he value of comparative approaches to assess potential
ntigenic regions using closely related Plasmodium species
ound inmacaques. I will show an example with genes encod-
ng a well known antigen, AMA-1. Then, I will review the
urrent status of our knowledge on the genetic diversity of
his parasite in Latin-America. Overall, P. vivax populations
n the new world have low levels of genetic diversity and
ndergo clonal expansions. Such low genetic polymorphism
hould be considered while using genetic markers in epi-
emiologic investigations that aim to assess, for example,
he frequency of recrudescent infections or the reintroduc-
ion/expansion of the parasite in a given geographic area in
he context of control efforts.
oi:10.1016/j.ijid.2010.02.2196
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reatment, Prophylaxis and Resistance in P. vivax Malaria
. Torres
Tropical Medicine Institute, Caracas, Venezuela
The burden of malaria caused by Plasmodium vivax
emains under-appreciated to a great extent, both in terms
f its clinical spectrum and incidence of disease. Con-
rol measures are hampered by both the emergence of
hloroquine (CQ) resistance and the presence of dormant
ypnozoite stages in the liver, which result in relapse infec-
